||||||||||STC3141 / China Grand Pharma Trial completion: A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019(COVID-19)Pneumonia (clinicaltrials.gov) - Apr 8, 2022 P2a, N=25, Completed, Sponsor: Grand Medical Pty Ltd. Neutralization of histone using STC3141, especially at high dose, had similar therapeutic effects to dexamethasone in this LPS double-hit rat ALI model, with significantly decreased circulating histone concentration, improved acute lung injury and oxygenation. Recruiting --> Completed
||||||||||STC3141 / China Grand Pharma Enrollment open: A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Dec 27, 2021 P1, N=16, Recruiting, Sponsor: Grand Medical Pty Ltd. Neutralization histone with STC3141in sepsis quickly stabilized hemodynamics with less NE utilization, ameliorated impaired microcirculation and improved tissue perfusion, which might provide a new therapeutic approach for sepsis. Not yet recruiting --> Recruiting